Resources

Full-Service CRO Overview

Full-Service CRO Overview

We are pleased to share Dr. Vince Clinical Research’s latest brochure, providing an in-depth overview of our full-service CRO solutions.
Effective Study Design and Execution of Renal and Hepatic Impairment Trials

Effective Study Design and Execution of Renal and Hepatic Impairment Trials

As most medications are primarily excreted through the kidneys or liver, most drugs in development will require a renal ...
How Including Cognition as a Safety Endpoint Provides a Competitive Differentiator

How Including Cognition as a Safety Endpoint Provides a Competitive Differentiator

In today’s rapidly evolving pharmaceutical landscape, cognitive safety is emerging as a critical factor that can set ...
From Chance Discovery to Molecular Biology

From Chance Discovery to Molecular Biology

Dr. Sheldon H. Preskorn's presentation, "From Chance Discovery to Molecular Biology," highlights the evolution of ...
Innovation in a First-In-Human Trial

Innovation in a First-In-Human Trial

With over 70,000 annual deaths, fentanyl overdose is the leading cause of death for Americans aged 18-45. In collaboration ...
Renal and Hepatic Impairment Studies

Renal and Hepatic Impairment Studies

Dr. Vince Clinical Research (DVCR) specializes in evaluating the effects of renal and hepatic impairments on drug ...
Accelerating Clinical & Drug Development Timelines with AI

Accelerating Clinical & Drug Development Timelines with AI

As the drug development landscape rapidly evolves, artificial intelligence (AI) is emerging as a transformative force, ...
Primary and Secondary Outcomes From a Phase I Study Comparing the Respiratory Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride Administration

Primary and Secondary Outcomes From a Phase I Study Comparing the Respiratory Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride Administration

Lynn Webster, MD, Executive Vice President of Scientific Affairs, recently presented his poster titled “A Review of the ...
Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access

Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access

Our Executive Vice President of Scientific Affairs, Dr. Lynn Webster, has released a co-authored review on opioid ...
Establishing Early Efficacy in Depression Clinical Trials

Establishing Early Efficacy in Depression Clinical Trials

This article is featured on The Association of Clinical Research Professionals (ACRP). Bradley D. Vince, DO and Sheldon H. ...
Updates on Human Abuse Potential Studies: Challenges and Regulatory Guidelines

Updates on Human Abuse Potential Studies: Challenges and Regulatory Guidelines

Discover this groundbreaking webinar delving into the latest insights from the CCALC and the FDA in drug development and clinical evaluation of human drug abuse and dependence potential.
3 Essential Components of Successful Renal and Hepatic Impairment Studies

3 Essential Components of Successful Renal and Hepatic Impairment Studies

Most drugs are eliminated from the body through some combination of vital organs, such as the small intestine, liver and/or ...